Keros Therapeutics, Inc. (KROS) › Shareholders' EquityKeros Therapeutics, Inc. (KROS) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2018: -$7.18M2019: -$19.45M2020: $261.72M2021: $243.17M2022: $277.42M2023: $332.21M2024: $571.55M2025: $303.13M$303.13M2018Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$303.13M-47.0%2024$571.55M+72.0%2023$332.21M+19.7%2022$277.42M+14.1%2021$243.17M-7.1%2020$261.72M+1445.9%2019-$19.45M-170.7%2018-$7.18M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share